Navigation Links
Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Date:10/25/2011

PITTSBURGH and POTTERS BAR, England, Oct. 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.K.-based subsidiary has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 mg and 6 mg. This product is the generic version of Novartis' Exelon® Capsules, a treatment for dementia in people with Alzheimer's disease. Mylan is the first company to launch a generic Rivastigmine formulation in the U.K.

Mylan Chairman and CEO Robert J. Coury said: "This is the second recent first-to-market generic for Mylan's business in the U.K., following the company's successful launch of Modafinil tablets, 100 mg, the generic version of Cephalon's Provigil®, earlier this year. We are excited to be adding generic Rivastigmine to our strong portfolio of more than 350 products in the U.K., and delivering on our brand's commitment of providing high quality and affordable medicines to patients around the world."

Rivastigmine Capsules POM had U.K. sales of approximately pounds Sterling 7.9 million for the last 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
2. Matrix Laboratories Completes Name Change to Mylan Laboratories
3. Mylan Announces Femcon® Fe Settlement Agreement
4. Mylan Announces Intention to Refinance Existing Secured Credit Facility
5. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
6. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
7. Mylan Announces XELODA® Settlement and License Agreement
8. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
9. Mylan Launches Generic Version of Uroxatral® Tablets
10. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
11. Mylan Launches First Generic Version of Entocort EC® Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):